Physician profile
Leonard Bielory
NPI 1154352987
$164,441.59
in general payments reported to CMS, 2019-2025
29 companies · $8,745 in 2025
The $8,745 reported for 2025 was more than what 93% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $74K · 2021: $31K · 2022: $8,895 · 2023: $8,951 · 2024: $3,721 · 2025: $8,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Honoraria: $3,647 · Food and Beverage: $1,666 · Travel and Lodging: $1,572 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,325.50 |
| Honoraria | $3,647.00 |
| Food and Beverage | $1,666.17 |
| Travel and Lodging | $1,571.62 |
| Education | $206.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $91,151.73 | 2020-2021 | |
| Covis Pharma Gmbh | $28,870.14 | 2019 | |
| Hikma Pharmaceuticals USA | $10,731.78 | 2021-2023 | Ryaltris |
| Csl Behring | $8,335.14 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech, INC. | $6,660.00 | 2022 | |
| Blueprint Medicines Corporation | $6,244.29 | 2022-2025 | Ayvakit |
| Ocular Therapeutix, INC. | $3,900.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $3,693.09 | 2020-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $3,495.00 | 2024 | |
| Biocryst US Sales Co., LLC | $208.15 | 2023-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $194.98 | 2025 | |
| Genzyme Corporation | $160.22 | 2019-2025 | |
| Alk-Abello, INC | $159.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $121.04 | 2023-2025 | Airsupra |
| Pharming Healthcare, INC. | $97.37 | 2019-2025 | Ruconest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $88.29 | 2020-2024 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $81.67 | 2019-2025 | Nucala |
| Optinose US, INC. | $50.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.21 | 2025 | |
| Pfizer INC. | $27.72 | 2023-2024 | |
| Cycle Pharmaceuticals INC | $20.70 | 2025 | Sajazir |
| Ars Pharmaceuticals Operations, INC. | $17.21 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $15.88 | 2025 | |
| Kaleo, INC. | $15.73 | 2019 | |
| Aimmune Therapeutics, INC. | $14.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.12 | 2019 | |
| Bio Products Laboratory USA, INC. | $13.75 | 2019 | |
| Shire North American Group INC | $11.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Bielory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.